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First published April 2, 2002; 10.1152/ajpendo.00424.2001.—
The extent and time course of suppression of endogenous
glucose production (EGP) in type 2 diabetes after a mixed
meal have been determined using a new tracer methodology.
Groups of age-, sex-, and weight-matched normal controls
(n  8) and diet-controlled type 2 diabetic subjects (n  8)
were studied after ingesting a standard mixed meal (550
kcal; 67% carbohydrate, 19% fat, 14% protein). There was an
early insulin increment in both groups such that, by 20 min,
plasma insulin levels were 266  54 and 190  53 pmol/l,
respectively. EGP was similar basally [2.55  0.12 mg kg1 
min1 in control subjects vs. 2.92  0.16 mg kg1 min1 in
the patients (P  0.09)]. After glucose ingestion, EGP de-
clined rapidly in both groups to 50% of basal within 30 min
of the meal. Despite the initial rapid decrease, the EGP was
significantly greater in the diabetic group at 60 min (1.75 
0.12 vs. 1.05  0.14 mg kg1 min1; P  0.01) and did not
reach nadir until 210 min (0.96  0.17 mg kg1 min1).
Between 60 and 240 min, EGP was 47% higher in the dia-
betic group (0.89  0.09 vs. 1.31  0.13 mg kg1 min1, P 
0.02). These data quantitate the initial rapid suppression of
EGP after a mixed meal in type 2 diabetes and the contribu-
tion of continuing excess glucose production to subsequent
hyperglycemia.
liver; insulin sensitivity
THE LIVER PLAYS A PRIMARY ROLE in maintaining the fast-
ing plasma glucose concentration within a very narrow
range in normal subjects, the basal rate of tissue glu-
cose uptake being precisely equaled by the rate of
endogenous glucose production (EGP). After the inges-
tion of a meal, this delicate balance is disrupted, and
maintenance of normal glucose homeostasis in the fed
state depends on suppression of EGP, augmentation of
glucose uptake by splanchnic tissues and muscle, and
stimulation of glucose oxidation (19). Because meals
tend to be taken every few hours during the day,
knowledge about these processes is central to the ap-
preciation of both normal energy metabolism and the
pathophysiology of non-insulin-dependent diabetes, a
condition characterized by marked postprandial hyper-
glycemia (10, 21, 30). Hepatic insulin resistance caus-
ing faulty control of glucose production is believed to
exacerbate the hyperglycemia (20, 27). The practical
importance of this has been emphasized by data link-
ing the extent of postprandial hyperglycemia with the
vascular complications of diabetes (18, 28).
Information on insulin regulation of glucose control
in the fed state has previously been inferred from
studies using intravenous glucose under the nonphysi-
ological condition of constant hyperinsulinemia. Many
studies have followed the fate of a pure glucose load
(24, 33, 37, 38), but the metabolic response to a glucose
load differs from that after a mixed meal (23, 35, 44).
Furthermore, the studies of endogenous glucose re-
lease after oral glucose have utilized a constant infu-
sion of a glucose tracer, such as that used during
steady-state glucose infusion experiments to achieve
constant specific activity of plasma glucose. However,
the key variable in the assessment of endogenous glu-
cose release is the tracer specific activity, referred not
to plasma glucose concentration but to endogenous
glucose concentration, i.e., that fraction of the plasma
glucose originating from endogenous sources. Because
the endogenous glucose concentration falls after eat-
ing, specific activity varies markedly during a constant
glucose tracer infusion protocol, leading to non-steady-
state errors in the calculation of EGP (15, 25, 34, 49).
To minimize non-steady-state errors, it is necessary to
reduce the changes in endogenous glucose specific ac-
tivity by use of a variable tracer infusion protocol.
Ideally, the tracer infusion is varied in such a way that
endogenous specific activity remains constant during
the meal absorption, and under these conditions the
calculation of EGP becomes model independent.
This alternative approach of varying the tracer infu-
sion rate was used as early as 1973 in experimental
work in dogs (22) but only recently in humans (65). The
technique has not previously been applied to type 2
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diabetes. By allowing direct measurement of both EGP
and plasma insulin after eating, the hypothesis that
insulin resistance operates at the level of the liver
could be tested. The absolute contribution of hepatic
dysregulation to postprandial hyperglycemia could
also be defined. This paper describes the pathophysio-
logical changes in EGP after a mixed meal by applying
the new technique to matched groups of normal and
type 2 diabetic subjects.
MATERIALS AND METHODS
Subjects. Type 2 diabetic subjects controlled for diet alone
(n  8) and age-, sex-, and weight-matched healthy volun-
teers (n  8) were recruited. Athletes in training were ex-
cluded, as were any subjects with metabolic disease or con-
trols with first-degree family history of type 2 diabetes. No
subject was taking medication that might affect carbohy-
drate metabolism. The mean duration of diabetes was 3.9 yr.
The clinical and metabolic characteristics of the subjects are
shown in Table 1. For 3 days before study, subjects consumed
their normal weight-maintaining diet and completed a di-
etary diary. The diabetic and control groups reported similar
calorie intakes (1,811 403 vs. 1,976 581 kcal) and similar
food composition (carbohydrate 239  46 vs. 252  77 g, fat
63 15 vs. 78 23 g, and protein 79 16 vs. 83 23 g). The
nature, purpose, and potential risks of the study were ex-
plained to all the subjects, and their informed, voluntary,
written consent was obtained before their participation. The
study protocol was reviewed and approved by the Joint Eth-
ics Committee, University of Newcastle upon Tyne.
Experimental protocol. Subjects were studied in the recum-
bent position after a 12-h overnight fast. At 7 AM, an intra-
venous cannula for infusion was placed in an antecubital
fossa vein, and a second cannula was placed in a distal
forearm vein in a retrograde fashion, this hand being placed
in a heated box at 50°C to allow sampling of arterialized
blood. At time 180 min a primed continuous (0.40 Ci/min)
infusion of [3-3H]glucose was started. The prime was 40 Ci
in the control group but was adjusted according to fasting
plasma glucose in the diabetic group to avoid delay in achiev-
ing steady-state plasma glucose specific activity (48). The
prime in 10 ml of normal saline was flushed through the
cannula with 5 ml of saline. A period of 180 min was allowed
for equilibrium of tritiated glucose; the end of this equilib-
rium period was taken to be time zero. A liquid meal (550
kcal; 67.3% carbohydrate, 18.5% fat, 14.2% protein) including
2 g of [2-2H]glucose was consumed within 10 min, starting at
time zero. After the meal, the rate of infusion of tritiated
glucose was adjusted to reproduce the anticipated pattern of
endogenous glucose release after the meal. Subjects voided
just before ingestion of the glucose load, and urine was
collected at 210 min (diabetic group only) and at the end of
the experiment for determination of urinary glucose loss.
Glucose oxidation rates were calculated from indirect calo-
rimetry data derived by use of a constant-flow hood calorim-
eter (Delta Trac 17). Measurements were made over 20-min
periods in the fasting state and at regular intervals after the
meal. Fuel oxidation data were calculated using equations of
Lusk (41). Frequent blood samples were taken for the deter-
mination of plasma glucose, [2-2H]glucose, [3-3H]glucose, lac-
tate, free fatty acids, insulin, and glucagon.
Variable tracer infusion rate. The [3-3H]glucose infusion
rate was varied in a stepwise fashion to anticipate the de-
crease and subsequent increase in EGP after the meal. The
protocol was determined iteratively in preliminary studies.
The variable infusion protocol remained the same for both
groups to avoid potential complicating factors, as the main
aim of the study was to compare the pattern of postprandial
EGP between the control and diabetic groups and was as
follows: basal period, 100% of basal infusion rate; 0–5 min,
100%; 5–10 min, 90%; 10–15 min, 75%; 15–20 min, 55%;
20–25 min, 40%; 25–30 min, 30%; 30–220 min, 20%; 220–
240 min, 30%; 240–260 min, 35%; 260–280 min, 40%; 280–
300 min, 45%; 300–400 min, 55%; and 400–480 min, 65%.
Calculations of EGP. The profile of exogenous glucose
concentration, i.e., the component of total glucose concentra-
tion due to exogenous glucose ingestion, was initially calcu-
lated. Because this is proportional to the concentration of
[2-2H]glucose, its calculation is straightforward and model
independent (16). We then calculated the time course of
endogenous glucose concentration, i.e., the component of to-
tal glucose concentration due to EGP only, by subtracting the
calculated exogenous component from the measured total
glucose concentration. The steady-state values of plasma
clearance rate (PCR) and basal EGP (basal EGP  PCR 
basal glucose concentration) were estimated from the
[3-3H]glucose decay curve after the primed continuous infu-
sion of [3-3H]glucose given 3 h before the administration of
the meal (14). Subsequently, the time course of EGP was
calculated from endogenous glucose concentration and
[3-3H]glucose data. Because [3-3H]glucose had been infused
to mimic the expected behavior of EGP, the specific activity
given by the ratio of [3-3H]glucose to endogenous glucose was
steady, thus allowing a more reliable estimation of EGP.
EGP was calculated using the two-compartment model of
Radziuk et al. (54). The concentration of [3-3H]glucose and
the ratio between [3-3H]glucose and endogenous glucose con-
centration were smoothed using an algorithm based on sto-
chastic nonparametric deconvolution (63).
Insulin sensitivity. The homeostatic model assessment
(HOMA) index of insulin sensitivity was calculated using
fasting insulin and glucose concentrations (43).
Analytical procedures. Plasma glucose concentration was
measured by the glucose oxidase method on a Beckman
glucose analyzer. Plasma insulin concentration was mea-
sured using an enzyme-linked immunosorbant assay kit
(Dako) and plasma glucagon by radioimmunoassay (50).
Plasma lactate was measured on perchloric acid extracts on
a Cobas Bio centrifugal analyzer (Roche, Welwyn Garden
City, UK) (29). Plasma FFA were measured by centrifugal
enzymatic analysis (39). Atom percent enrichment of plasma
[2-2H]glucose was determined by gas chromatography-mass
spectrometry (8). Plasma [3-3H]glucose radioactivity was de-
termined after deproteinization of plasma with ZnS04 and
Ba(OH)2, as described (56).
Statistical methods. Data are stated as means  SE. Stu-
dent’s two-tailed t-test and Pearson’s correlation were em-
ployed as appropriate with the use of the Minitab statistical
program (Minitab, State College, PA).
Table 1. Clinical characteristics of the study subjects
Characteristic Normal Subjects Diabetic Subjects
Age, yr 50.82.9 52.42.9
Sex, M/F 5/3 5/3
Body mass index 29.61.3 30.11.2
Fasting glucose, mmol/l 5.00.1 7.70.5
Hb A1C, % 5.50.1 7.20.4
Values are means  SE.
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RESULTS
Plasma glucose. After glucose ingestion, plasma glu-
cose in the control group increased from a basal level of
4.8  0.1 mmol/l to peak concentration of 7.8  0.4
mmol/l at 60 min and returned to basal values between
180 and 240 min (Fig. 1). In the diabetic subjects,
plasma glucose increased from a basal level of 6.8 1.2
mmol/l to a peak concentration of 14.2  2.2 mmol/l at
150 min (both P  0.001 compared with controls) and
did not return to basal levels until 330 min. The mean
plasma glucose concentration in the diabetic subjects
during the 8-h experimental period was 9.5 mmol/l
compared with 5.7 mmol/l in the control group (P 
0.001). The rise in enrichment of [2-2H]glucose in
plasma was very similar in the two groups, diverging
modestly only after 80 min (Fig. 2).
Plasma metabolites and hormones. There was no
significant difference in the fasting insulin concentra-
tion in the two groups (50  10 pmol/l in controls vs.
67  12 pmol/l in patients, P  0.23). After glucose
ingestion, there was an early, brisk increment in both
groups such that, by 20 min, plasma insulin levels were
266  54 and 190  53 pmol/l in the control and
diabetic groups, respectively. Plasma insulin increased
to a peak concentration at 60 min in the control group
(614  179 pmol/l) and more slowly to peak concentra-
tion at 150 min in the diabetic group (449 123 pmol/l;
Fig. 1). In the control group, plasma insulin levels
returned to basal values between 240 and 270 min, but
in the diabetic group basal levels were not reached
until 400 min after the meal. Immediately before the
meal, plasma glucagon concentrations were similar in
the two groups (53.3  6.0 ng/l in control vs. 59.7 
10.4 ng/l in patients, P  0.3). After glucose ingestion,
plasma glucagon rose briskly in both groups to peak at
20 min (69.6  vs. 94.2  15.1 ng/l, respectively, P 
0.17; Fig. 1). Plasma glucagon decreased in the control
group to 36.6  2.3 ng/l at 150 min and returned to
basal values between 300 and 360 min. In the diabetic
subjects, the plasma glucagon at 150 min was still
elevated at 74.0  12.9 ng/l (P  0.03) and did not
reach lowest concentrations until 270 min. Plasma
lactate levels were similar in control and diabetic sub-
jects both fasting (0.66  0.14 vs. 0.58  0.07 mM) and
at peak (80 min: 0.95  0.11 vs. 1.02  0.14 mM). The
subsequent fall in plasma lactate was slightly but not
significantly delayed in the diabetic subjects (150 min:
0.65  0.04 vs. 0.99  0.18 mM, respectively).
Endogenous glucose output. Steady-state plasma lev-
els of [3-3H]glucose were achieved in the basal period
(Fig. 3).
Fasting EGP was 2.55  0.12 mg kg1 min1 in
control subjects vs. 2.92  0.16 mg kg1 min1 in the
patients (P  0.09). After glucose ingestion, EGP de-
clined rapidly in both groups to 50% of basal within
30 min of the meal (Fig. 4). The parallel rates of decline
in EGP over this 30-min period are striking. In control
subjects EGP decreased further and remained less
than 1 mg kg1 min1 until 240 min but recovered
steeply thereafter. The greatest suppression was ob-
served at 120 min (0.75  0.16 mg kg1 min1). De-
spite the initial rapid decrease in EGP in the diabetic
group, the EGP was significantly greater than in con-
Fig. 1. Plasma specific activity during the primed continuous infu-
sion of [3H]glucose during the basal period before the test meal.
Fig. 2. Change in plasma glucose (A), insulin (B), and glucagon
concentrations (C) after the test meal in the type 2 diabetic group (F)
and the matched normal control group (E). Data are shown as
means  SE.
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trols at 60 min (1.75  0.12 vs. 1.05  0.14
mg kg1 min1, P  0.01) and did not reach nadir
until 210 min (0.96  0.17 mg kg1 min1). Between
60 and 240 min, EGP was 47% higher in the diabetic
group (0.89 0.09 vs. 1.31 0.13 mg kg1 min1, P
0.02). EGP recovered rapidly in nondiabetic subjects
between 240 and 360 min, plateauing thereafter. In the
diabetic subjects the rise was less rapid (0.006 vs. 0.011
mg kg1 min1; Fig. 5).
At 60 min after the meal, the degree of suppression
of EGP correlated both with plasma insulin (r0.60,
P  0.02) and with the insulin/glucagon ratio (r 
0.63, P  0.01; Fig. 6). There was an inverse corre-
lation between the HOMA index of insulin sensitivity
and EGP 60 min after the meal in both the control (r 
0.81, P 0.02) and diabetic groups (r 0.82, P 0.02).
Plasma FFA. Fasting FFA concentration was higher
in the diabetic group (0.48  0.03 vs. 0.69  0.08
mmol/l, P  0.05). Plasma FFA concentration fell to
0.09  0.05 mmol/l at 80 min in the control group (Fig.
5). After remaining suppressed for over 3 h, plasma
FFA concentration rebounded, reaching 0.87  0.06
mmol/l at 460 min. In the diabetic group, FFA concen-
tration had fallen by 80 min, but it remained elevated
compared with controls (0.35  0.01 mmol/l, P 
0.005). The lowest concentration was not reached until
270 min (0.20  0.10 mmol/l, P  0.05 compared with
controls at 80 min).
Glucose oxidation. Net glucose oxidation rate in the
basal state was higher in the control than the diabetic
group (1.69 0.14 vs. 1.14 0.10 mg kg1 min1, P
0.01). The rate of rise was similar in both groups such
that, at peak net glucose oxidation rate in the control
group (180 min), there was a significant difference
between the groups (2.35  0.22 vs. 1.69  0.25 mg 
kg1 min1, P  0.05; Fig. 7). In the diabetic group,
Fig. 3. Top: rate of absorption of meal glucose shown as atom percent
excess of 2-D-glucose in plasma in the type 2 diabetic group (F) and
the matched normal control group (E). Bottom: specific activity (SA)
of endogenously derived glucose in plasma expressed as percentage
of basal plasma glucose specific activity.
Fig. 4. Change in endogenous glucose production (EGP) during the
early postmeal phase in the type 2 diabetic group (F) and the
matched normal control group (E). Data are shown as means  SE.
Fig. 5. A: time course of EGP during the entire study period after the
test meal. B: molar ratio of plasma glucagon to insulin. C: change in
plasma free fatty acid (FFA) concentration after the test meal in the
type 2 diabetic group (F) and the matched normal control group (E).
The vertical dashed line at 40 min is included to assist comparison
between the relative time courses. Data are shown as means  SE.
E278 ENDOGENOUS GLUCOSE PRODUCTION IN TYPE 2 DIABETES
AJP-Endocrinol Metab • VOL 283 • AUGUST 2002 • www.ajpendo.org
 o
n
 O
ctober 7, 2011
ajpendo.physiology.org
D
ow
nloaded from
 
peak rates were achieved at 240 min (1.82  0.26
mg kg1 min1). In both groups, carbohydrate oxida-
tion rates declined thereafter.
Urinary glucose excretion. During the early post-
prandial period (0–210 min), urinary glucose excretion
rate was 0.29 0.22 mg kg1 min1, and between 210
and 480 min it was 1.9  0.9 mg kg1 min1 in the
diabetic group. There was no quantifiable loss of glu-
cose in urine in the control group.
DISCUSSION
This study demonstrates the time course and extent
of suppression of EGP after a mixed meal in subjects
with type 2 diabetes. The initial rate of suppression
was similar in the diabetic and matched control groups
but was not sustained in the diabetic group, such that
EGP was 47% higher between 60 and 240 min after
eating. This is important, as meals are normally taken
every 4–5 h during waking hours. The nadir of EGP
was delayed by 120 min, and, unlike in the control
group, this was not sustained. In both groups, plasma
insulin increased briskly during the initial 20 min.
Subsequently, plasma insulin in the type 2 diabetic
group rose more slowly to a subnormal peak. Con-
versely, plasma glucagon concentrations were higher
in the diabetic group throughout the postprandial pe-
riod. One hour after the meal, the degree of suppres-
sion of EGP correlated with plasma insulin and with
the insulin/glucagon ratio.
Hepatic insulin resistance is widely believed to play
an important role in the pathophysiology of type 2
diabetes (5, 20, 27). The observed modest elevation of
fasting plasma insulin in the type 2 diabetic subjects,
together with the slightly elevated EGP and the sub-
normal suppression of EGP between 60 and 240 min,
are consistent with this. However, the present data
indicate that the response to a similar acute increment
in hepatic sinusoidal insulin concentration produces
the same initial rate of suppression of EGP in type 2
diabetic subjects and matched controls (Fig. 4). These
observations were made under the normal day-to-day
circumstances of elevated plasma glucose and glucagon
in type 2 diabetes, and direct inferences about hepatic
insulin sensitivity cannot be made. Glucose effective-
ness in suppression of EGP is similar in normal and
diabetic subjects (4); hence, the elevated plasma glu-
cose will exert an additional suppressive effect in the
diabetic group. However, the apparently normal acute
hepatic insulin responsiveness under everyday condi-
tions is of interest. In contrast to the universal obser-
vation of insulin resistance of muscle in type 2 diabe-
tes, normal insulin sensitivity of the liver has
previously been reported by use of exogenous insulin
infusion to mimic postprandial profiles (36). The same
group demonstrated a normal rate of onset of hepatic
insulin action (68). In obese type 2 diabetic subjects,
elevation of plasma insulin to a mean of 30 mU/l was
observed to be associated with fall in EGP of 51 vs. 54
Fig. 7. Change in glucose oxidation rates after the meal in the type
2 diabetic group (F) and the matched normal control group (E). Data
are shown as means  SE.
Fig. 6. Relationships between EGP 60 min after the meal and
plasma insulin at 60 min (A), plasma glucagon/insulin ratio (B), and
homeostatic model assessment (HOMA) index of insulin sensitivity
(C).
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mg m2 min1 in control and diabetic groups, respec-
tively (64). The present data confirm the everyday
physiological relevance of acute insulin responsiveness
of the liver in type 2 diabetes, although between 60 and
240 min after eating, higher ambient insulin levels do
not achieve normal suppression of EGP. Because glu-
cose transport is the major insulin-insensitive step in
muscle in type 2 diabetes (57), and because glucose
transport is not rate limiting for hepatic glucose me-
tabolism, it would be expected that liver and muscle
differ in expression of insulin resistance. It is notewor-
thy that postprandial EGP correlated with HOMA, an
index based on the fasting state. The data on EGP
reported in the present study includes a renal compo-
nent, and the latter has been reported to rise after
eating (45).
The control subjects demonstrated a prompt de-
crease in EGP, although this was less rapid than pre-
viously observed in young normal subjects (66), and
possible reasons for this must be considered. The meals
in the two studies were made up of identical propor-
tions of carbohydrate, protein, and fat, although the
total energy content was modestly less in the present
study (550 vs. 650 kcal). It is unlikely that this had a
major impact on initial rates of EGP suppression. Age
per se is unlikely to be responsible, as neither periph-
eral nor hepatic insulin sensitivity changes with age,
provided physical activity and obesity are matched
(11). The considerable difference in body mass index
(BMI; 30 vs. 21 kg/m2) between the previously studied
subjects and the control subjects in the present study
may explain the observations. Obesity itself could be
exerting an effect by changing the availability of intra-
hepatic fatty acids in the hepatic sinusoids (7). In the
present study, the two groups were well matched for
BMI. The diabetic and control groups demonstrated an
identical rate of suppression of EGP over the first 30
min after commencing the meal. However, suppression
of EGP was much slower in the diabetic group there-
after. This pattern of abnormality raises the question
of precisely which factors regulate EGP during the
postprandial period. Both the major regulatory hor-
mones (31, 40, 42) and change in plasma FFA (6) have
to be considered.
The rate of rise in plasma insulin concentration in
the first 20 min (6.4 pmol  l1 min1) in this group of
diabetic subjects was striking and at 20 min repre-
sented 40.1% of the subsequent peak concentration
compared with 43.3% in the control subjects. Although
the initial insulin response to eating may appear un-
expectedly great for subjects with type 2 diabetes,
previous studies of such subjects after a mixed meal
rather than pure glucose have reported a similar
change in plasma insulin (59). The ability of intrave-
nous arginine to elict normal early insulin-secretory
responses in type 2 diabetes has been recognized for
many years (51). The mixed meal administered in the
present study would bring about a stimulus to the
pancreas by the increment in plasma amino acids and
glucose as happens in everyday life. The subjects were
at a relatively early stage of the disease and were
reasonably well controlled on diet alone. The actual
change in hepatic sinusoidal insulin concentration will
be underestimated by measurements on peripheral
plasma samples. Portal vein insulin concentrations are
2.4-fold greater than peripheral plasma concentra-
tions during steady-state conditions (12), and during
the initial phase of increasing insulin concentration
the degree of increase over basal will be considerably
greater. Hence, in the 20 min after eating, the liver
would be exposed to an increase in insulin concentra-
tion from 160 pmol/l (2.4 times peripheral levels) to
well over 460 pmol/l in the diabetic group. This consid-
erable change could be supramaximal with respect to
inducing initial change in EGP, the increase to 630
pmol/l in the controls achieving only a similar rate of
suppression of EGP. The subsequent pattern of insulin
secretion differs markedly between the groups (Fig. 1),
and the sustained difference is consistent with the
slower subsequent suppression of EGP in the diabetic
group between 60 and 240 min. This analysis of change
in the concentrations of one hormone does not by itself
explain the pattern of the EGP response to insulin, and
the effect of simultaneous change in glucagon concen-
tration must be considered.
Glucagon exerts a powerful effect on EGP (31).
Plasma glucagon levels increased more markedly in
the diabetic group (Fig. 1), and, during the important
phase from 60 to 240 min after eating, plasma glucagon
levels were elevated approximately twofold in the dia-
betic group compared with the controls. Similar data in
type 2 diabetes have previously been reported (2, 62).
This is generally consistent with an effect on the ob-
served pattern of EGP but, as with the pattern of
change of insulin, it does not match the time course of
change in EGP in the two groups. However, if the
hormones are regarded as part of a coordinated re-
sponse to eating and the molar ratio of glucagon to
insulin is calculated, a different picture emerges. It can
be seen from Fig. 5 that the glucagon/insulin ratio
changes in a manner highly suggestive of this being the
major regulatory factor. A similar close relationship
was previously observed in the study of young healthy
subjects (66). Although the concept of dual regulation
of EGP by glucagon and insulin is not new (69), it has
not previously been linked so closely to physiological
regulation in vivo.
Several previous studies have indicated a role for
FFA in controlling EGP (9, 13, 26, 52, 55, 60). The
“single gateway hypothesis” was originally put forward
to integrate observations on change in plasma hor-
mones and FFA, suggesting that peripheral action of
hormones exerted effects on the liver primarily by
modulating plasma FFA concentrations (6). However,
some studies have not observed any effect of FFA on
EGP (53, 58), and evidence exists to suggest that insu-
lin acts directly to inhibit EGP (42). In the present
study, FFA concentration did not change in control and
diabetic groups, respectively, in the 20 min after eat-
ing, whereas EGP fell by 25 and 35%, respectively, over
the same time. In the 40 min after eating, FFA concen-
tration fell by 42 and 14% in control and diabetic
E280 ENDOGENOUS GLUCOSE PRODUCTION IN TYPE 2 DIABETES
AJP-Endocrinol Metab • VOL 283 • AUGUST 2002 • www.ajpendo.org
 o
n
 O
ctober 7, 2011
ajpendo.physiology.org
D
ow
nloaded from
 
groups, and EGP fell by 59 and 57%, respectively, over
the same time. The relatively slow and small change in
plasma FFA has to be compared with the major rapid
changes in plasma insulin and glucagon. The compar-
ative time courses are shown in Fig. 6. There were,
however, weak correlations between basal FFA and the
extent of suppression of EGP (r  0.54, P  0.05) and
between the decrease of FFA concentrations at 40 min
and the time to maximum suppression of EGP (r 
0.58, P  0.05). The observations do not support the
concept of an important acute role for plasma FFA in
regulating EGP but do not exclude the possibility of
regulation over longer periods. It has recently been
demonstrated that 8 h of lipid infusion blunted sup-
pression of EGP during a hyperinsulinemic clamp (61).
Non-steady-state errors in the estimation of EGP can
be avoided if the tracer specific activity of endogenous
glucose is maintained constant during meal absorp-
tion. If a continuous infusion of tracer is used through-
out the postprandial period, the specific activity will
rise sharply as EGP is suppressed. By steady-state
theory, this will cause EGP to be overestimated after a
meal and, hence, create the appearance of slow sup-
pression (15, 25, 34, 49). Indeed, previous studies using
a constant tracer infusion after an oral glucose load
have reported slow suppression in both normal and
diabetic subjects to 20–50% of basal EGP (24, 33, 46).
A similar problem of overestimation has been identi-
fied if tracer specific activity is increasing during esti-
mation of fasting EGP (48). In the present study, this
difficulty was avoided in the basal state by adequate
priming of the glucose pool and in the postprandial
state by adjusting the rate of tracer infusion in a
stepwise manner to match the expected decrease in
EGP. Our previous work (66) in young healthy sub-
jects demonstrated that constant specific activity of
endogenous glucose could be achieved using this
technique. Previous work on human subjects has
demonstrated normal rates of glucose absorption in
type 2 diabetes (3).
Knowledge of the dynamics of change in EGP after
eating, coupled with observations on whole body glu-
cose oxidation rates, allows an analysis of the factors
underlying postprandial hyperglycemia in type 2 dia-
betes. During the 30 min after eating, the suppression
of EGP did not account for any major difference be-
tween control and diabetic groups. However, by 60 min
after eating, plasma glucose had reached maximum in
the controls, but in the diabetic group it was still rising
at 2.1 mg kg1 min1 (Fig. 1). At 60 min, the differ-
ence in EGP between the groups was 0.70
mg kg1 min1 (Fig. 4), this representing 33% of the
excess accumulation of glucose in extracellular fluid.
The difference in glucose oxidation rates was 0.63
mg kg1 min1, or 30% of the excess accumulation of
glucose. The remainder must be accounted for by inad-
equate rates of glucose disposal. It can thus be seen
that inadequate suppression of EGP, subnormal glu-
cose oxidation rate, and slow tissue uptake of glucose
are each an important factor in the genesis of postpran-
dial hyperglycemia in type 2 diabetes. Previous studies
using magnetic resonance spectroscopy have demon-
strated that, at 5 h after eating in nondiabetic subjects,
20% of the absorbed carbohydrate is stored in liver
and 30% in muscle (65, 67). This is very different from
the pattern during hyperinsulinemic clamp studies.
Previous evidence suggests that the relative disposi-
tion of glucose in muscle and liver differs considerably
after oral and intravenous routes (1, 32, 47). In conclu-
sion, direct study of the pathophysiological changes
after eating has allowed quantitation of the major
factors underlying postprandial hyperglycemia in type
2 diabetes.
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